Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas

NCT01744249 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

256

Enrollment

OTHER

Sponsor class

Conditions

Neuroendocrine Tumors
Advanced Cancer

Interventions

DRUG: Axitinib
DRUG: Sandostatin LAR
DRUG: Placebo

Sponsor

Grupo Espanol de Tumores Neuroendocrinos

Collaborators

[object Object]